Citations 4
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
Hiwase, Devendra , Hahn, Christopher N , Tran, Elizabeth Ngoc Hoa , Chhetri, Rakchha , Al‐Kali, Aref , Sharplin, Kirsty, Ladon, Dariusz, Hollins, Rachel, Greipp, Patricia T. , Kutyna, Monika , Badar, Talha , Bardy, Peter, Beligaswatte, Ashanka , Litzow, Mark R. , Mangaonkar, Abhishek A. , Giri, Pratyush, Yong, Angie, Horvath, Noemi , Singhal, Nimit , Gowda, Raghu , Gangat, Naseema , Patnaik, Mrinal M. , Begna, Kebede H. , Wei, Andrew H. , Kumar, Sharad , Scott, Hamish S. , Tefferi, Ayalew , Hahn, Christopher , Al-Kali, Aref , Greipp, Patricia T , Badar, Talha , Ross, David M , Singhal, Deepak , Shanmuganathan, Naranie , Litzow, Mark R. , Gangat, Naseema , Patnaik, Mrinal , Begna, Kebede , Tiong, Ing Soo , Wei, Andrew H , Kumar, Sharad , Brown, Anna L , Scott, Hamish , Shah, Mithun V , Hiwase, Devendra , Kutyna, Monika M , Baranwal, Anmol , Alkhateeb, Hassan B. , Wang, Paul Po-Shen , Singhal, Deepak , Yeung, David , Lee, Cindy , Hogan, William J. , Brown, Anna , THOMAS, DANIEL W. , Kok, Chung Hoow , Shah, Meera
Blood | December 27, 2022 | Volume: 141 | Issue: 9 | Pages: 1087-1091
TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
Sharplin, Kirsty, Chhetri, Rakchha , Ladon, Dariusz, Al‐Kali, Aref , Litzow, Mark R. , Mangaonkar, Abhishek A. , Gangat, Naseema , Patnaik, Mrinal M. , Begna, Kebede, Tefferi, Ayalew , Shah, Meera , Hahn, Christopher N , Tran, Elizabeth Ngoc Hoa , Baranwal, Anmol , Kutyna, Monika , Wang, Paul Po-Shen , Alkhateeb, Hassan B. , Ross, David M , Yeung, David , Shanmuganathan, Naranie , Hogan, William J. , Kumar, Sharad , Singhal, Deepak , Brown, Anna , Scott, Hamish S. , THOMAS, DANIEL W. , Kok, Chung Hoow , Hiwase, Devendra
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9798-9799
Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
Ladon, Dariusz, Chhetri, Rakchha , Sharplin, Kirsty, Al‐Kali, Aref , Gangat, Naseema , Litzow, Mark R. , Kebede, Ashanka Begna, Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Tefferi, Ayalew , Kok, Chung Hoow , Tran, Elizabeth Ngoc Hoa , Baranwal, Anmol , Alkhateeb, Hassan B. , Singhal, Deepak , Yeung, David , Ross, David M , Hogan, William J. , Shanmuganathan, Naranie , Kumar, Sharad , THOMAS, DANIEL W. , Shah, Meera , Hiwase, Devendra
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6962-6963
Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53therapy-Related Myeloid Neoplasm Patients with Poor Outcome
Chhetri, Rakchha , Al‐Kali, Aref , Gangat, Naseema , Litzow, Mark R. , Begna, Kebede, Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Tefferi, Ayalew , Shah, Meera , Hahn, Christopher N , Tran, Elizabeth Ngoc Hoa , Singhal, Deepak , Hogan, William J. , Kutyna, Monika , Alkhateeb, Hassan B. , Baranwal, Anmol , Shanmuganathan, Naranie , Kumar, Sharad , THOMAS, DANIEL W. , Kok, Chung Hoow , Hiwase, Devendra
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6964-6965